专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06306847B1 Condensed purine derivatives 失效
标题翻译：凝血嘌呤衍生物
公开(公告)号：US06306847B1
公开(公告)日：2001-10-23
申请号：US09090936
申请日：1998-06-05
申请人： Hiroshi Tsumuki , Mayumi Saki , Hiromi Nonaka , Michio Ichimura , Junichi Shimada , Fumio Suzuki , Shunji Ichikawa , Nobuo Kosaka
发明人： Hiroshi Tsumuki , Mayumi Saki , Hiromi Nonaka , Michio Ichimura , Junichi Shimada , Fumio Suzuki , Shunji Ichikawa , Nobuo Kosaka
IPC分类号： C07D48714
CPC分类号： C07D487/14
摘要： The present invention provides condensed purine derivatives or pharmacologically acceptable salts thereof exhibiting adenosine A3 acceptor antagonising activity, and having an antiasthmatic action, a bronchodilator action, an antiantiitching action, etc., and represented by the following formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents hydrogen, lower alkyl, alicyclic alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; R3 represents hydrogen, lower alkyl, or substituted or unsubstituted aralkyl; X1 and X2 are the same or different and each represents hydrogen, lower alkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted aryl; and n represents an integer of 0 to 3).
摘要翻译：本发明提供具有腺苷A3受体拮抗活性的缩合嘌呤衍生物或其药理学上可接受的盐，并具有抗哮喘作用，支气管扩张剂作用，抗脱除作用等，并由下式（I）表示:(其中R1表示取代或未取代的芳基或取代或未取代的芳族杂环基; R 2表示氢，低级烷基，脂环族烷基，取代或未取代的芳烷基，取代或未取代的芳基或取代或未取代的芳族杂环基; R 3表示氢，低级烷基或取代或未取代的芳烷基; X 1和X 2相同或不同，各自表示氢，低级烷基，取代或未取代的芳烷基或取代或未取代的芳基; n表示0〜3的整数。

2. 发明授权

US06222035B1 [1,2,4] triazolo [1,5-C] pyrimidine derivatives 失效
标题翻译： [1,2,4]三唑并[1,5-C]嘧啶衍生物
公开(公告)号：US06222035B1
公开(公告)日：2001-04-24
申请号：US09401984
申请日：1999-09-23
申请人： Hiroshi Tsumuki , Junichi Shimada , Hironori Imma , Akiko Nakamura , Hiromi Nonaka , Shizuo Shiozaki , Shunji Ichikawa , Tomoyuki Kanda , Yoshihisa Kuwana , Michio Ichimura , Fumio Suzuki
发明人： Hiroshi Tsumuki , Junichi Shimada , Hironori Imma , Akiko Nakamura , Hiromi Nonaka , Shizuo Shiozaki , Shunji Ichikawa , Tomoyuki Kanda , Yoshihisa Kuwana , Michio Ichimura , Fumio Suzuki
IPC分类号： C07D48700
CPC分类号： C07D487/04
摘要： [1,2,4]Triazolo[1,5-c]pyrimidine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof are provided, which have adenosine A2A receptor antagonism and are useful for the treatment or prevention of various diseases induced by hyperactivity of adenosine A2A receptors (for example, Parkinson's disease or senile dementia): wherein R1 represents substituted or unsubstituted aryl, or the like; R2 represents hydrogen, halogen, lower alkyl, substituted or unsubstituted aryl, or the like; R3 represents hydrogen, halogen, XR10 (wherein X represents O or S; and R10 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aralkyl, lower alkyl, or hydroxy lower alkyl), or the like; and Q represents hydrogen or 3,4-dimethoxybenzyl.
摘要翻译： [1,2,4]具有式（I）表示的三唑并[1,5-c]嘧啶衍生物或其药学上可接受的盐，其具有腺苷A2A受体拮抗作用，可用于治疗或预防由腺苷A2A受体（例如帕金森病或老年性痴呆）的多动症：其中R1表示取代或未取代的芳基等; R 2表示氢，卤素，低级烷基，取代或未取代的芳基等; R3表示氢，卤素，XR10（其中X表示O或S; R10表示取代或未取代的芳基，取代或未取代的芳族杂环，取代或未取代的芳烷基，低级烷基或羟基低级烷基）等; Q表示氢或3,4-二甲氧基苄基。

3. 发明授权

US5756735A Xanthine derivatives 失效
标题翻译：黄嘌呤衍生物
公开(公告)号：US5756735A
公开(公告)日：1998-05-26
申请号：US483159
申请日：1995-06-07
申请人： Fumio Suzuki , Akio Ishii , Hiromi Nonaka , Nobuo Kosaka , Shunji Ichikawa , Junichi Shimada
发明人： Fumio Suzuki , Akio Ishii , Hiromi Nonaka , Nobuo Kosaka , Shunji Ichikawa , Junichi Shimada
IPC分类号： C07D473/06
CPC分类号： C07D473/06
摘要： The present invention relates to novel xanthine derivatives of the formula (I) which are selectively antagonistic to an adenosine A.sub.2 receptor, and pharmaceutically acceptable salts thereof. Formula (I): ##STR1## In the formula, R.sup.1 and R.sup.2 are the same or different and each represents a hydrogen atom, a propyl group, a butyl group or an allyl group; R.sup.3 represents a hydrogen atom or a lower alkyl group; Y.sup.1 and Y.sup.2 are the same or different and each represents a hydrogen atom or a methyl group; and Z represents a substituted or unsubstituted phenyl group, a pyridyl group, an imidazolyl group, a furyl group or a thienyl group.
摘要翻译：本发明涉及对腺苷A2受体选择性拮抗的式（I）的新颖黄嘌呤衍生物及其药学上可接受的盐。式（I）：（I）式中，R 1和R 2相同或不同，表示氢原子，丙基，丁基或烯丙基; R3表示氢原子或低级烷基; Y1和Y2相同或不同，各自表示氢原子或甲基; Z表示取代或未取代的苯基，吡啶基，咪唑基，呋喃基或噻吩基。

4. 发明授权

US5484920A Therapeutic agent for Parkinson's disease 失效
标题翻译：帕金森病治疗剂
公开(公告)号：US5484920A
公开(公告)日：1996-01-16
申请号：US133510
申请日：1993-10-07
申请人： Fumio Suzuki , Junichi Shimada , Nobuaki Koike , Joji Nakamura , Shizuo Shioazaki , Shunji Ichikawa , Akio Ishii , Hiromi Nonaka
发明人： Fumio Suzuki , Junichi Shimada , Nobuaki Koike , Joji Nakamura , Shizuo Shioazaki , Shunji Ichikawa , Akio Ishii , Hiromi Nonaka
IPC分类号： C07D473/06 , C07D473/08 , C07D473/12 , A61K31/52
CPC分类号： C07D473/08 , C07D473/06 , C07D473/12
摘要： Agents for the treatment of Parkinson's disease contain, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## in which R.sup.1, R.sup.2 are R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 represents cycloalkyl, --(CH.sub.2).sub.n --R.sup.5 (in which R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or ##STR2## in which Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, ##STR3## in which R.sup.6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 represent independently O or S.
摘要翻译：用于治疗帕金森病的药物含有作为活性成分的黄嘌呤衍生物或其药学上可接受的盐。黄嘌呤衍生物由下式表示：其中R 1，R 2为R 3独立地为氢，低级烷基，低级烯基或低级炔基; 并且R 4表示环烷基， - （CH 2）n -R 5（其中R 5表示取代或未取代的芳基或取代或未取代的杂环基; n为0至4的整数）或其中Y 1和Y 2表示独立地是氢，卤素或低级烷基; Z表示取代或未取代的芳基，其中R 6表示氢，羟基，低级烷基，低级烷氧基，卤素，硝基或氨基; m表示1〜4的整数，或取代或未取代的杂环基; X1和X2独立地表示O或S.

5. 发明授权

US5587378A Therapeutic agent for Parkinson's disease 失效
标题翻译：帕金森病治疗剂
公开(公告)号：US5587378A
公开(公告)日：1996-12-24
申请号：US447885
申请日：1995-05-23
申请人： Fumio Suzuki , Junichi Shimada , Nobuaki Koike , Joji Nakamura , Shizuo Shiozaki , Shunji Ichikawa , Akio Ishii , Hiromi Nonaka
发明人： Fumio Suzuki , Junichi Shimada , Nobuaki Koike , Joji Nakamura , Shizuo Shiozaki , Shunji Ichikawa , Akio Ishii , Hiromi Nonaka
IPC分类号： C07D473/06 , C07D473/08 , C07D473/12 , A61K31/52
CPC分类号： C07D473/08 , C07D473/06 , C07D473/12
摘要： Methods for the treatment of Parkinson's disease comprising administering to a patient an agent which contains, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 is cycloalkyl, --(CH.sub.2).sub.n --R.sup.5, wherein R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4, or ##STR2## wherein Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z is substituted or unsubstituted aryl, ##STR3## wherein R.sup.6 is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m is an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 are independently O or S.
摘要翻译：用于治疗帕金森病的方法包括向患者施用含有作为活性成分的黄嘌呤衍生物或其药学上可接受的盐的试剂。黄嘌呤衍生物由下式表示：其中R 1，R 2和R 3独立地是氢，低级烷基，低级链烯基或低级炔基; 并且R 4是环烷基， - （CH 2）n -R 5，其中R 5表示取代或未取代的芳基或取代或未取代的杂环基; n为0〜4的整数，或者，其中Y1和Y2独立地表示氢，卤素或低级烷基; Z是取代或未取代的芳基，其中R6是氢，羟基，低级烷基，低级烷氧基，卤素，硝基或氨基; m为1〜4的整数，或取代或未取代的杂环基; X1和X2独立地为O或S.

6. 发明授权

US5703085A Xanthine derivatives 失效
标题翻译：黄嘌呤衍生物
公开(公告)号：US5703085A
公开(公告)日：1997-12-30
申请号：US537770
申请日：1995-10-20
申请人： Fumio Suzuki , Nobuaki Koike , Junichi Shimada , Joji Nakamura , Shizuo Shiozaki , Shigeto Kitamura , Shunji Ichikawa , Hiroshi Kase , Hiromi Nonaka
发明人： Fumio Suzuki , Nobuaki Koike , Junichi Shimada , Joji Nakamura , Shizuo Shiozaki , Shigeto Kitamura , Shunji Ichikawa , Hiroshi Kase , Hiromi Nonaka
IPC分类号： C07D473/06 , A61K31/52 , C07D473/10 , C07D473/12
CPC分类号： C07D473/06
摘要： The present invention relates to novel xanthine derivatives and pharmaceutically acceptable salts thereof, represented by Formula (I): ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl, R.sup.4 represents lower alkyl, or substituted or unsubstituted aryl, R.sup.5 and R.sup.6 independently represent hydrogen, lower alkyl, and lower alkoxy, or R.sup.5 and R.sup.6 are combined together to represent --O--(CH.sub.2)p--O-- (p is an integer of 1 to 3), n represents 0, 1, or 2, and m represents 1 or 2. The compounds of the present invention have an adenosine A.sub.2 receptor antagonistic activity, and are useful for the treatment or prevention of various kinds of diseases caused by hyperergasia of adenosine A.sub.2 receptors (for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis).
摘要翻译： PCT No.PCT / JP95 / 00267 Sec。 371 1995年10月20日第 102（e）1995年10月20日日期PCT提交1995年2月23日PCT公布。公开号WO95 / 23148 日期：1995年8月31日本发明涉及由式（I）表示的新颖的黄嘌呤衍生物及其药学上可接受的盐：其中R1，R2和R3独立地表示氢，低级烷基，低级链烯基或低级炔基，R 4表示低级烷基或取代或未取代的芳基，R 5和R 6独立地表示氢，低级烷基和低级烷氧基，或者R 5和R 6结合在一起代表-O-（CH 2）p O-（p是整数 1〜3），n表示0,1或2，m表示1或2.本发明化合物具有腺苷A2受体拮抗活性，可用于治疗或预防各种疾病腺苷A2受体（例如帕金森病，老年性痴呆，抑郁症，哮喘和骨质疏松症）的过度高血症。

7. 发明申请

US20060252679A1 Preventive and/or trerapeutic drgs for itch 审中-公开
标题翻译：预防和/或治疗性瘙痒
公开(公告)号：US20060252679A1
公开(公告)日：2006-11-09
申请号：US10525324
申请日：2003-08-22
申请人： Mayumi Saki , Hiromi Nonaka , Hiromasa Miyaji , Shunji Ichikawa , Chiemi Takashima , Tsutomu Matsumura , Hitoshi Arai , Katsutoshi Sasaki , Choei Kobatake , Yukihito Tsukumo , Kyoichiro Iida , Takeshi Kuboyama , Haruhiko Manabe
发明人： Mayumi Saki , Hiromi Nonaka , Hiromasa Miyaji , Shunji Ichikawa , Chiemi Takashima , Tsutomu Matsumura , Hitoshi Arai , Katsutoshi Sasaki , Choei Kobatake , Yukihito Tsukumo , Kyoichiro Iida , Takeshi Kuboyama , Haruhiko Manabe
IPC分类号： A61K38/17 , A61K48/00
CPC分类号： C07D401/14 , A61K31/519 , A61K31/55 , A61K31/7088 , A61K48/00 , C07D403/06 , C07D417/14 , C07D471/04 , G01N33/5088
摘要： The present invention provides an agent for prevention and/or treatment of itching comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient. It also provides a nitrogen-containing tricyclic compound represented by the formula (I) or a quaternary ammonium salt thereof, or a pharmaceutically acceptable salt thereof; [wherein R1 represents substituted or unsubstituted lower alkyl, etc.; R2 represents hydrogen, substituted or unsubstituted lower alkyl, etc.; R3 and R4 are the same or different and each represents hydrogen, lower alkyl, etc.; n represents 0 or 1; X represents —(CH2)2—, etc.; and Y represents the formula (II); (wherein W represents CH or a nitrogen atom; Z1 and Z2 are the same or different and each represents hydrogen, substituted or unsubstituted lower alkyl, etc.; and Z3 represents hydrogen, substituted or unsubstituted lower alkyl, etc.)]
摘要翻译：本发明提供了用于预防和/或治疗瘙痒的药剂，其包含能够抑制作为活性成分的GPR4的信号转导所涉及的功能的物质。它还提供由式（I）表示的含氮三环化合物或其季铵盐或其药学上可接受的盐; [其中R 1表示取代或未取代的低级烷基等; R 2表示氢，取代或未取代的低级烷基等; R 3和R 4相同或不同，各自表示氢，低级烷基等; n表示0或1; X表示 - （CH 2 2）2 - 等; Y表示式（II）; （其中W表示CH或氮原子; Z 1和Z 2相同或不同，各自表示氢，取代或未取代的低级烷基等; Z 代表氢，取代或未取代的低级烷基等）]

8. 发明授权

US5543415A Antidepressants 失效
标题翻译：抗抑郁药
公开(公告)号：US5543415A
公开(公告)日：1996-08-06
申请号：US199142
申请日：1994-02-25
申请人： Fumio Suzuki , Junichi Shimada , Akio Ishii , Joji Nakamura , Shunji Ichikawa , Shigeto Kitamura , Nobuaki Koike
发明人： Fumio Suzuki , Junichi Shimada , Akio Ishii , Joji Nakamura , Shunji Ichikawa , Shigeto Kitamura , Nobuaki Koike
IPC分类号： F16B37/04 , A61K31/00 , A61K31/52 , B29C65/08 , B29C65/72 , C07D473/06 , C07D473/08 , C07D473/12 , C07D473/20 , C07D473/22 , A61K31/505
CPC分类号： A61K31/52 , C07D473/06 , C07D473/08 , F16B37/048
摘要： The present invention relates to an antidepressant containing as an active ingredient a xanthine derivative or a pharmaceutically acceptable salt thereof, the xanthine derivative being represented by Formula (I) : ##STR1## in which R.sup.1, R.sup.2, and R.sup.3 represent independently hydrogen, lower alkyl, lower alkenyl;R.sup.4 represents cycloalkyl, --(CH.sub.2).sub.n --R.sup.5 (in which R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or ##STR2## (in which Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen or lower alkyl; and Z represents substituted or unsubstituted aryl, ##STR3## (in which R.sup.6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 3), or a substituted or unsubstituted heterocyclic group);and X.sup.1 and X.sup.2 represent independently O or S.
摘要翻译： PCT No.PCT / JP93 / 00931 Sec。 371日期1994年2月25日 102（e）1994年2月25日PCT PCT 1993年7月7日PCT公布。第WO94 / 01114号公报日本时间1994年1月20日本发明涉及含有作为活性成分的黄嘌呤衍生物或其药学上可接受的盐的抗抑郁药，黄嘌呤衍生物由式（I）表示：其中R1，R2，并且R 3独立地表示氢，低级烷基，低级烯基; R 4表示环烷基， - （CH 2）n -R 5（其中R 5表示取代或未取代的芳基或取代或未取代的杂环基; n为0〜4的整数）或

9. 发明授权

US5565460A Therapeutic purine agents for parkinson's disease 失效
标题翻译：治疗帕金森病的嘌呤药物
公开(公告)号：US5565460A
公开(公告)日：1996-10-15
申请号：US367346
申请日：1995-03-03
申请人： Fumio Suzuki , Junichi Shimada , Nobuaki Koike , Shunji Ichikawa , Joji Nakamura , Tomoyuki Kanda , Shigeto Kitamura
发明人： Fumio Suzuki , Junichi Shimada , Nobuaki Koike , Shunji Ichikawa , Joji Nakamura , Tomoyuki Kanda , Shigeto Kitamura
IPC分类号： A61K31/505 , A61K31/53 , C07D487/04 , A61K31/535 , A61K31/54
CPC分类号： C07D487/04 , A61K31/505 , A61K31/53
摘要： The present invention relates to a therapeutic agent for Parkinson's disease containing as an active ingredient a polycyclic compound or a pharmaceutically acceptable salt thereof, the compound being represented by the following Formula (I): ##STR1## and A represents N or CR.sup.5 (in which R.sup.5 represents hydrogen, or substituted or unsubstituted lower alkyl), or represented by the following Formula (II): ##STR2## wherein Y, R.sup.6 and R.sup.8 are as defined herein and B and the adjacent two carbon atoms are combined to form a substituted or unsubstituted, partially saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic group.
摘要翻译： PCT No.PCT / JP94 / 01196 Sec。 371日期1995年3月3日 102（e）1995年3月3日PCT PCT 1994年7月20日PCT公布。公开号WO95 / 03806 日期：1995年2月9日本发明涉及含有作为活性成分的多环化合物或其药学上可接受的盐的帕金森病治疗剂，该化合物由下式（I）表示：＆lt; IMAGE＆gt;（I）和 A表示N或CR 5（其中R 5表示氢或取代或未取代的低级烷基），或由下式（II）表示：其中Y，R 6和R 8如本文所定义，B和相邻的两个碳原子结合形成取代或未取代的，部分饱和或不饱和的单环或双环，碳环或杂环基团。

10. 发明授权

US5789407A Method of treating depression with certain triazine derivatives 失效
标题翻译：用某些三嗪衍生物治疗抑郁症的方法
公开(公告)号：US5789407A
公开(公告)日：1998-08-04
申请号：US424397
申请日：1995-04-25
申请人： Fumio Suzuki , Nobuaki Koike , Junichi Shimada , Shigeto Kitamura , Shunji Ichikawa , Joji Nakamura , Shizuo Shiozaki
发明人： Fumio Suzuki , Nobuaki Koike , Junichi Shimada , Shigeto Kitamura , Shunji Ichikawa , Joji Nakamura , Shizuo Shiozaki
IPC分类号： A61K31/53 , C07D487/04 , A61K31/535
CPC分类号： C07D487/04 , A61K31/53
摘要： The present invention relates to an antidepressant containing as an active ingredient a triazine derivative or a pharmaceutically acceptable salt thereof, the derivative being represented by the following Formula (I): ##STR1## in which, R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower alkanoyl; R.sup.2 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heterocyclic group; R.sup.3 represents a substituted or unsubstituted heterocyclic group; X represents a single bond, O, S, S(O), S(O).sub.2, or NR.sup.4 (in which R.sup.4 represents hydrogen, or substituted or unsubstituted lower alkyl; or R.sup.2 and NR.sup.4 are combined to form a substituted or unsubstituted 4 to 6-membered saturated heterocyclic group); and A represents N or CR.sup.5 (in which R.sup.5 represents hydrogen, or substituted or unsubstituted lower alkyl).
摘要翻译： PCT No.PCT / JP94 / 01455 Sec。 371日期1995年04月25日 102（e）日期1995年4月25日PCT 1994年9月2日PCT公布。公开号WO95 / 07282 日期：1995年3月16日本发明涉及含有作为活性成分的三嗪衍生物或其药学上可接受的盐的抗抑郁药，该衍生物由下式（I）表示：其中，R 1表示氢，取代或未取代的低级烷基或取代或未取代的低级烷酰基; R 2表示氢，取代或未取代的低级烷基，取代或未取代的低级烯基，取代或未取代的环烷基，取代或未取代的芳基，取代或未取代的芳烷基或取代或未取代的杂环基; R3表示取代或未取代的杂环基; X表示单键，O，S，S（O），S（O）2或NR4（其中R4表示氢或取代或未取代的低级烷基;或R2和NR4组合形成取代或未取代的4 至6元饱和杂环基）; A表示N或CR5（其中R5表示氢或取代或未取代的低级烷基）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式